Spaceballs 2 Won't Be Here Till 2027, but You Can Stream the Original Spaceballs Right Now
Legendary comedian Mel Brooks is approaching his 99th birthday later this month, and the spry filmmaker still has a few surprises up his sleeve, including a recent shocking announcement that the classic sci-fi parody Spaceballs would be releasing a sequel, Spaceballs 2.
If the news has your Schwartz tingling, you're not alone. The comedy icon dropped a teaser confirming that the long-rumored sequel is officially happening and will hit theaters in 2027.
The upcoming film will feature returning stars Bill Pullman and Rick Moranis, alongside a new cast that includes Keke Palmer and Josh Gad. It's described as a "non-prequel non-reboot sequel part two, but with reboot elements franchise expansion film," which feels perfectly on-brand for a movie that once sold branded toilet paper as a punchline.
Where to watch the original Spaceballs
If you're not willing to wait until 2027 to revisit Planet Spaceball, you can stream the original Spaceballs now.
The Max streaming service, which will soon reclaim the HBO Max name, has the 1987 sci-fi spoof available for your viewing pleasure. Spaceballs stars Brooks, Moranis, Pullman, John Candy, and the voice of Joan Rivers in a galaxy-sized send-up of Star Wars. It's the kind of throwback movie that isn't made much these days, even in the form of the silly Scary Movie franchise, so there are plenty of reasons to be appreciative that a sequel is on its way.
The original 1987 parody Spaceballs stars Bill Pullman, Daphne Zuniga, the voice of Joan Rivers and John Candy.
Metro-Goldwyn-Mayer Studios Inc.
The original film is now a cult classic thanks to its rapid-fire gags, absurd characters, hilarious takes on familiar sci-fi and the reverence we have for movies like Star Wars. And hey, it's a Mel Brooks creation, so you know it's full of laughs.
If it's been a while since you watched Lone Starr fly a Winnebago through space or you just want to hear Dark Helmet shout "I am your father's brother's nephew's cousin's former roommate" again, now's the perfect time to take the original Spaceballs for another spin. Or show it to someone for the very first time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
'Materialists' Totally Set Dakota Johnson's Character for Up Failure and You Can't Convince Us Otherwise
Materialists poses the question of whether or not we should be going for love or for money and the choice Dakota Johnson's character makes has people on internet divided The film also stars Pedro Pascal and Chris Evans Materialists is in theaters nowMovies have long wanted to convince us that we should be marrying for love. From The Notebook to Titanic, films have always suggested that women should follow their hearts and go for the sweet charmer with no money instead of the well-established gentleman who has financial stability. (Granted, Billy Zane's character in Titanic was awful, but stay with me here.) Well, Materialists has repurposed that trope once again, and the internet is seething. The film follows Lucy (played by Dakota Johnson), a successful matchmaker who has managed to find love for everyone except for herself. Her skills are immediately tested when she finds herself in a love triangle with Harry (played by Pedro Pascal), a successful billionaire who errs on the side of superficiality but is offering her the world, vs. John (played by Chris Evans), her ex-boyfriend, who offers her lots of love and affection, but works from gig to gig while trying to get an acting career off the ground. The film takes us through all the hijinks of a romcom as both men have their pros and cons and try to woo her. In the end, Lucy goes for John, the broke boy who loves her dearly, but can't provide her with the lifestyle she always dreamed of. And while the internet is upset over the fact that Pedro Pascal doesn't get the girl, the truth of the matter is, Lucy was set up for failure from the jump. As PEOPLE editor Bailey Richards pointed out. Regardless of whom she was going to end up with, Lucy was going to be settling. "I don't think she should have ended up with either of them," Richards says, considering Bailey's options. "Marry this hot, caring man who will pay for everything for you for the rest of your life — any materialistic whim you may have. He doesn't love you, but he will pay anything. Or a hot, caring man who does love you, but makes no money ... he will drop anything, at any given moment to do whatever for you." We can all agree that the only real winners are Lucy's children (if she wants any), who will 100% win the genetic lottery regardless of which guy she chooses. However, when it comes to meeting the standards Lucy deeply desires, she's bound to lose regardless. So, instead of settling for the loverboy with no money, Richards believes Lucy should have actually axed both men. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "After everything that she, as a matchmaker, as a woman, goes through in that movie, she just needs to break from romance altogether and do some introspection, the kind that requires you to be single and be alone," says Richards. Personally, the right choice for me is always Pedro Pascal. But I have to agree with my colleague here. Relationships are hard, even when you find everything you want in a person, so why give yourself more heartache by settling for someone who doesn't meet your standards? Read the original article on People
Associated Press
35 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
35 minutes ago
- Associated Press
MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency. 'This innovation is about biology meeting infrastructure,' says Tanawade. 'We've discovered how nature's mechanisms can dramatically extend the life of our clean energy systems.' Unlike conventional synthetic cooling solutions, MountBay's microbial approach is circular, biodegradable, and scalable—opening up new frontiers for climate resilience and fire-risk reduction in hot environments. The research aligns perfectly with MountBay's mission to power the AI economy through clean, sustainable, and advanced infrastructure. It also positions the company as a frontrunner in biological material integration across the energy sector. Additionally, MountBay has released a preliminary transformative feasibility report for a Lunar Solar Belt—a continuous solar array on the Moon that can beam uninterrupted, clean energy back to Earth. The report outlines how in-situ resource utilization (ISRU), autonomous lunar robotics, and microwave power transmission could enable the construction of a moon-based solar plant by the 2030s. With an energy return on investment (EROI) of 8:1, the system offers a scalable, emission-free solution to humanity's growing power demands. 'This is not just an energy project—it's a civilization-scale investment in global stability,' said Tanawade. 'We believe the Moon should be a cooperative utility, not a geopolitical race.' MountBay is also proposing a new diplomatic framework—The Earth-Moon Energy Accord (EMEA)—to ensure equitable access, safety, and international cooperation. The concept directly supports MountBay's mission: to push the frontiers of clean power while securing energy independence for AI-driven economies. Tanawade is rallying governments, institutions, and innovators to join him. 'It's time for America to lead the most ambitious energy project in human history,' he said. Media Contact: Vrushabhraj Tanawade Founder @ MountBay Energy Contact : [email protected] Website: Linkedin: Linkedin - Vrushabhraj T Disclaimer: This press release is provided by MountBay Energy. The statements, views, and opinions expressed are solely those of the provider and do not necessarily reflect those of this media platform or its publisher. Any names or brands mentioned are used for identification purposes only and remain the property of their respective owners. No endorsement or guarantee is made regarding the accuracy, completeness, or reliability of the information presented. This material is for informational purposes only and does not constitute financial, legal, or professional advice. Readers are encouraged to conduct independent research and consult qualified professionals. The publisher is not liable for any losses, damages, or legal issues arising from the use or publication of this content. Photos accompanying this announcement are available at:
